PNC Financial Services Group Inc. Sells 225,894 Shares of Bristol Myers Squibb Company $BMY

PNC Financial Services Group Inc. cut its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 6.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,433,534 shares of the biopharmaceutical company’s stock after selling 225,894 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Bristol Myers Squibb were worth $185,205,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Saranac Partners Ltd grew its stake in Bristol Myers Squibb by 6.7% during the fourth quarter. Saranac Partners Ltd now owns 6,806 shares of the biopharmaceutical company’s stock worth $367,000 after purchasing an additional 425 shares during the period. Larson Financial Group LLC lifted its stake in Bristol Myers Squibb by 2.2% in the fourth quarter. Larson Financial Group LLC now owns 28,890 shares of the biopharmaceutical company’s stock valued at $1,558,000 after buying an additional 635 shares during the period. Handelsbanken Fonder AB boosted its holdings in shares of Bristol Myers Squibb by 12.5% during the 4th quarter. Handelsbanken Fonder AB now owns 1,269,920 shares of the biopharmaceutical company’s stock worth $68,499,000 after buying an additional 140,901 shares in the last quarter. Profund Advisors LLC boosted its holdings in shares of Bristol Myers Squibb by 16.8% during the 4th quarter. Profund Advisors LLC now owns 37,994 shares of the biopharmaceutical company’s stock worth $2,049,000 after buying an additional 5,470 shares in the last quarter. Finally, ProShare Advisors LLC grew its position in shares of Bristol Myers Squibb by 3.5% during the 4th quarter. ProShare Advisors LLC now owns 397,535 shares of the biopharmaceutical company’s stock worth $21,443,000 after buying an additional 13,369 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on BMY. Barclays began coverage on shares of Bristol Myers Squibb in a research report on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Cantor Fitzgerald increased their price objective on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 8th. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Sunday, April 19th. Finally, HSBC boosted their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday, March 17th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $61.31.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a strategic agreement with Anthropic to make Claude Enterprise available across its global operations, including more than 30,000 employees, with use cases spanning research, drug development, manufacturing, and commercial functions. The deal may help accelerate discovery and lower operating friction. Article Title
• Positive Sentiment: Multiple reports confirmed Bristol Myers Squibb is deploying Anthropic’s Claude AI tools to speed up drug discovery and broaden AI adoption across the company, reinforcing the market’s view that BMY is investing in productivity-enhancing technology. Article Title
• Positive Sentiment: Tempus AI also announced an expanded collaboration with Bristol Myers Squibb to improve clinical trial design and increase the probability of success across five development programs, which supports the company’s pipeline execution story. Article Title
• Neutral Sentiment: Coverage pieces from Seeking Alpha, Yahoo Finance, and Zacks indicate BMY is a closely watched stock right now, but these items appear more descriptive than fundamentally new. Article Title
• Neutral Sentiment: Recent commentary also continues to focus on pipeline hopes, patent risks, and valuation moves, which keep investor attention on long-term execution rather than near-term financial results. Article Title

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.05% of the stock is currently owned by company insiders.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $58.45 on Thursday. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The firm has a fifty day simple moving average of $58.48 and a two-hundred day simple moving average of $55.73. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The firm has a market capitalization of $119.37 billion, a PE ratio of 16.42, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the company earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts forecast that Bristol Myers Squibb Company will post 6.31 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.